SETH LERNER to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications SETH LERNER has written about Xenograft Model Antitumor Assays.
Connection Strength
0.108
-
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015 Jan 08; 517(7533):209-13.
Score: 0.024
-
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3377-82.
Score: 0.023
-
The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3383-9.
Score: 0.023
-
A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. Urol Oncol. 2013 Feb; 31(2):234-40.
Score: 0.019
-
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther. 2010 May; 9(5):1128-35.
Score: 0.018